AbbVie - Coronavirus (COVID-19) Response

AbbVie is donating $35 million to help support underserved communities and healthcare systems working to address the impact of the COVID-19 global pandemic. AbbVie’s partners are International Medical Corps, Direct Relief, and Feeding America. Included in the $35 million is a reserve of $5 million for a new AbbVie COVID-19 Community Resilience Fund. The Fund will provide up to $1 million each in financial support to organizations strengthening community resilience in under-resourced areas impacted by COVID-19.

AbbVie is also doubling the AbbVie Foundation match for COVID-19-related contributions by employees. The AbbVie Foundation will match $2 to every $1 employees donate to a qualified nonprofit.

AbbVie is collaborating with global health authorities and institutions, including the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), World Health Organization (WHO), among others, to evaluate any potential antiviral activity as well as efficacy and safety of KALETRA® /Aluvia (lopinavir/ritonavir)* against COVID-19. The company also joined the Innovative Medicines Initiative to support research and discovery of targeted medicines against COVID-19.

AbbVie has supplied KALETRA/Aluvia as an experimental option for the treatment of COVID-19 to multiple countries that have immediate patient needs due to the outbreak, including donating product to the Chinese government in the early days of their fight against the virus.
 
While helping respond to the coronavirus crisis is a high priority for the company, it is committed to protecting the supply of KALETRA/Aluvia for existing patients.